Nothing Special   »   [go: up one dir, main page]

DK3986890T3 - Benzisoxazol-sulfonamid-derivater - Google Patents

Benzisoxazol-sulfonamid-derivater Download PDF

Info

Publication number
DK3986890T3
DK3986890T3 DK20743773.2T DK20743773T DK3986890T3 DK 3986890 T3 DK3986890 T3 DK 3986890T3 DK 20743773 T DK20743773 T DK 20743773T DK 3986890 T3 DK3986890 T3 DK 3986890T3
Authority
DK
Denmark
Prior art keywords
sulfonamide derivatives
benzisoxazole
benzisoxazole sulfonamide
derivatives
sulfonamide
Prior art date
Application number
DK20743773.2T
Other languages
English (en)
Inventor
Ylva Elisabet Bergman Bozikis
Oleg Brodsky
Michelle Ang Camerino
Samantha Elizabeth Greasley
Robert Louis Hoffman
Robert Arnold Kumpf
Pei-Pei Kung
Paul Francis Richardson
Paul Anthony Stupple
Scott Channing Sutton
Original Assignee
Pfizer
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Ctxt Pty Ltd filed Critical Pfizer
Application granted granted Critical
Publication of DK3986890T3 publication Critical patent/DK3986890T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK20743773.2T 2019-06-18 2020-06-16 Benzisoxazol-sulfonamid-derivater DK3986890T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863199P 2019-06-18 2019-06-18
US201962953223P 2019-12-24 2019-12-24
US202063025278P 2020-05-15 2020-05-15
PCT/IB2020/055589 WO2020254946A1 (en) 2019-06-18 2020-06-16 Benzisoxazole sulfonamide derivatives

Publications (1)

Publication Number Publication Date
DK3986890T3 true DK3986890T3 (da) 2023-12-18

Family

ID=71738189

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20743773.2T DK3986890T3 (da) 2019-06-18 2020-06-16 Benzisoxazol-sulfonamid-derivater

Country Status (30)

Country Link
US (2) US11492346B2 (da)
EP (2) EP3986890B1 (da)
JP (2) JP7352662B2 (da)
KR (1) KR20220024671A (da)
CN (1) CN114364672B (da)
AU (2) AU2020296361A1 (da)
BR (1) BR112021025528A2 (da)
CA (1) CA3143666C (da)
CL (1) CL2021003372A1 (da)
CO (1) CO2021017504A2 (da)
CR (1) CR20210627A (da)
DK (1) DK3986890T3 (da)
EC (1) ECSP21091615A (da)
ES (1) ES2969616T3 (da)
FI (1) FI3986890T3 (da)
HR (1) HRP20231501T1 (da)
HU (1) HUE064683T2 (da)
IL (1) IL288802A (da)
LT (1) LT3986890T (da)
MD (1) MD3986890T2 (da)
MX (1) MX2021016085A (da)
PE (1) PE20220808A1 (da)
PH (1) PH12021553107A1 (da)
PL (1) PL3986890T3 (da)
PT (1) PT3986890T (da)
RS (1) RS64931B1 (da)
SI (1) SI3986890T1 (da)
TW (1) TWI787620B (da)
UY (1) UY38752A (da)
WO (1) WO2020254946A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
JP2022534425A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
BR112021025528A2 (pt) * 2019-06-18 2022-04-19 Ctxt Pty Ltd Derivados de sulfonamida de benzisoxazol
US20220251075A1 (en) * 2019-06-19 2022-08-11 Pfizer Inc. Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives
CN116113407A (zh) * 2020-07-15 2023-05-12 辉瑞公司 用于癌症治疗的kat6抑制剂方法及组合
US20220024919A1 (en) * 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022187688A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent kras-binding compounds for therapeutic purposes
WO2022187693A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent cdk2-binding compounds for therapeutic purposes
IL308667A (en) * 2021-05-21 2024-01-01 Aurigene Oncology Ltd Fused isoxazolyl compounds as kat6a inhibitors
WO2023280182A1 (zh) * 2021-07-05 2023-01-12 杭州英创医药科技有限公司 作为kat6抑制剂的化合物
MX2024001777A (es) 2021-08-10 2024-02-29 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.
WO2023088233A1 (en) 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
TW202400593A (zh) 2022-03-28 2024-01-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ家族離胺酸乙醯轉移酶之抑制劑
AU2023295547A1 (en) * 2022-06-16 2025-01-09 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
AU2023315227A1 (en) 2022-07-29 2025-02-13 Ctxt Pty Ltd Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
CN118221643A (zh) * 2022-12-20 2024-06-21 杭州中美华东制药有限公司 具有sting抑制作用的含肟化合物及其药物组合物和用途
TW202434600A (zh) * 2023-02-10 2024-09-01 大陸商江蘇恒瑞醫藥股份有限公司 磺醯胺衍生物結晶形式及其製備方法
TW202440097A (zh) * 2023-03-27 2024-10-16 大陸商北京康辰藥業股份有限公司 磺醯胺化合物、其藥物組合物和用途
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2024217563A1 (en) * 2023-04-19 2024-10-24 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitor, combinations and uses thereof
WO2024222725A1 (en) * 2023-04-25 2024-10-31 Insilico Medicine Ip Limited Crystalline lysine acetyltransferase 6a (kat6a) inhibitor and uses thereof
WO2025007873A1 (zh) * 2023-07-04 2025-01-09 上海齐鲁制药研究中心有限公司 Kat6抑制剂

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3064003A (en) 1962-11-13 Carboxylic acid derivatives of sub-
US2358031A (en) 1944-09-12 Substituted thiadiazoles
US2525321A (en) 1949-01-07 1950-10-10 American Cyanamid Co Hydroxybenzenesulfonamidoisoxazoles and preparation of same
GB689281A (en) 1950-02-18 1953-03-25 Lunbeck Corp Improvements in or relating to the production of sulphanilamido-thiadiazoles
DE1102745B (de) 1959-06-06 1961-03-23 Boehringer & Soehne Gmbh Verfahren zur Herstellung von 5-Sulfanilamidoisoxazolen
BE617370A (fr) 1961-05-09 1962-11-08 Ciba Geigy Procédé de préparation du 2,5-di-[benzoxazolyl-(2')]-thiofène
US3332942A (en) 1962-11-02 1967-07-25 White Lab Inc Substituted thiadiazoles
JPS498255B1 (da) 1970-10-08 1974-02-25
US3951967A (en) 1972-03-20 1976-04-20 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
US3960854A (en) 1972-03-20 1976-06-01 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
DE2617809C2 (de) 1976-04-23 1984-09-20 Basf Ag, 6700 Ludwigshafen Verfahren zur Stabilisierung von Chromdioxid-Magnetpigmenten und seine Verwendung
JPS6042794B2 (ja) 1977-09-27 1985-09-25 三共株式会社 イソオキサゾリウム塩，およびその製造方法
US4251664A (en) 1978-05-24 1981-02-17 Henkel Corporation Sulfonamidothiadiazoles, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS603685B2 (ja) 1980-04-15 1985-01-30 日本コロムビア株式会社 絵入りレコ−ド盤の製造方法
GB8427618D0 (en) 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS63238006A (ja) 1987-03-26 1988-10-04 Shionogi & Co Ltd イモチ防除剤
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ231534A (en) 1988-11-29 1992-02-25 Warner Lambert Co 3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions
JPH03258771A (ja) 1990-03-09 1991-11-19 Tosoh Corp スルホンアミド誘導体、その製法及びそれを有効成分として含有する除草剤
TW224462B (da) 1992-02-24 1994-06-01 Squibb & Sons Inc
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
CA2121724A1 (en) 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
JP3901229B2 (ja) 1994-05-13 2007-04-04 Ｎｔｎ株式会社 耐熱・潤滑性樹脂組成物
EP0819125B1 (en) 1995-04-04 2003-06-18 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AU7179598A (en) 1996-11-13 1998-06-03 Cephalon, Inc. Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
EP0980369B1 (en) 1997-04-28 2005-03-30 Encysive Pharmaceuticals Inc. Sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
MX228790B (es) 1999-09-17 2005-06-30 Millennium Pharm Inc Inhibidores del factor xa.
AU2456701A (en) 1999-12-31 2001-07-16 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
GB0127344D0 (en) 2001-11-14 2002-01-02 Cancer Res Ventures Ltd Assay method
MXPA04004842A (es) 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
JP2003292485A (ja) 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
AU2004240885A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
CN1867334A (zh) 2003-07-22 2006-11-22 詹森药业有限公司 作为c－fms激酶抑制剂的喹啉酮衍生物
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
US8202861B2 (en) 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
AU2005295902A1 (en) 2004-10-12 2006-04-27 Decode Genetics Ehf Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
EP1888558B1 (en) 2005-05-16 2011-10-05 Vertex Pharmaceuticals, Inc. Bicyclic derivatives as modulators of ion channels
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
BRPI0616800A2 (pt) 2005-10-06 2011-06-28 Sanofi Aventis n-[1,3,4]-tiadiazol-2-il-benzeno sulfonamidas, processos para sua preparação e seu uso como produtos farmacêuticos
RU2008113209A (ru) 2005-10-06 2009-10-10 Санофи-Авентис (Fr) Бициклические {1, 3, 4}тиадиазол-2-иламиды арилсульфоновой кислоты, способы их получения и их использование в качестве фармацевтических средств
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
US7799822B2 (en) 2005-12-21 2010-09-21 Vertex Pharmaceuticals Incorporated Phenyl sulfonamides as modulators of ion channels
EP2054056A4 (en) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
EP2099792A1 (en) 2006-11-20 2009-09-16 Alantos Pharmaceuticals Holding, Inc. Heterotricyclic metalloprotease inhibitors
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
US20110039847A1 (en) 2007-11-01 2011-02-17 Sirtris Pharmaceuticals, Inc Amide derivatives as sirtuin modulators
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009080223A1 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Cyclic pyridyl-n-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
US8475505B2 (en) 2008-08-13 2013-07-02 Smed-Ta/Td, Llc Orthopaedic screws
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
WO2010121963A1 (en) 2009-04-21 2010-10-28 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as hsp90 inhibitors
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CN101845043A (zh) 2010-01-15 2010-09-29 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
CN101747325A (zh) 2010-01-15 2010-06-23 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
WO2011085575A1 (zh) 2010-01-15 2011-07-21 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
EP2563761A1 (en) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
CN103298460B (zh) 2010-12-14 2016-06-01 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
CA2898680A1 (en) 2013-03-15 2014-09-18 Genentech,Inc. Substituted benzoxazoles and methods of use thereof
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
WO2015112465A1 (en) 2014-01-24 2015-07-30 Merck Sharp & Dohme Corp. Isoquinoline derivatives as mgat2 inhibitors
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017002120A1 (en) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
EP3548480A1 (en) * 2016-11-29 2019-10-09 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
BR112021025528A2 (pt) 2019-06-18 2022-04-19 Ctxt Pty Ltd Derivados de sulfonamida de benzisoxazol

Also Published As

Publication number Publication date
PL3986890T3 (pl) 2024-03-11
FI3986890T3 (fi) 2024-01-15
PE20220808A1 (es) 2022-05-20
TW202115048A (zh) 2021-04-16
KR20220024671A (ko) 2022-03-03
LT3986890T (lt) 2023-12-11
MX2021016085A (es) 2022-04-20
EP4299135A3 (en) 2024-02-28
AU2020296361A1 (en) 2022-01-06
US11492346B2 (en) 2022-11-08
MD3986890T2 (ro) 2024-04-30
CL2021003372A1 (es) 2022-10-07
EP3986890A1 (en) 2022-04-27
IL288802A (en) 2022-02-01
ES2969616T3 (es) 2024-05-21
TWI787620B (zh) 2022-12-21
RS64931B1 (sr) 2023-12-29
CA3143666C (en) 2024-06-11
WO2020254946A1 (en) 2020-12-24
JP7352662B2 (ja) 2023-09-28
PH12021553107A1 (en) 2022-08-01
SI3986890T1 (sl) 2024-03-29
CO2021017504A2 (es) 2022-01-17
HRP20231501T1 (hr) 2024-03-01
US20200399258A1 (en) 2020-12-24
AU2023274178A1 (en) 2024-02-15
CN114364672B (zh) 2024-09-06
HUE064683T2 (hu) 2024-04-28
BR112021025528A2 (pt) 2022-04-19
CR20210627A (es) 2022-02-08
CN114364672A (zh) 2022-04-15
ECSP21091615A (es) 2022-01-31
JP2023175821A (ja) 2023-12-12
PT3986890T (pt) 2024-01-17
UY38752A (es) 2021-01-29
US20230174522A1 (en) 2023-06-08
JP2022537285A (ja) 2022-08-25
EP4299135A2 (en) 2024-01-03
CA3143666A1 (en) 2020-12-24
EP3986890B1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
DK3986890T3 (da) Benzisoxazol-sulfonamid-derivater
PT3958977T (pt) Derivados de camptotecina
EP3994692C0 (en) BINARY COMPUTING CELL IN MEMORY
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
IL292161A (en) New methylquinazolinone derivatives
EP3833739A4 (en) STRAIN OF AKKERMANSIA MUCINIPHILA
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP3926701A4 (en) BILLBOARD
DK3768669T3 (da) Piperazinazaspiroderivater
EP3973221C0 (de) Stop & go-molch
EP3789383A4 (en) BENZISOXAZOLE COMPOUND
IL283900A (en) Pharmaceutical combinations
EP3773566A4 (en) OX2R COMPOUNDS
AR120804A1 (es) Derivados de isoxazolina
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
EP3982415A4 (en) BILLBOARD
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
DK3796975T3 (da) Sulfonylaminobenzamidderivater
EP4034170A4 (en) TGF-BETA RELATED POLYPEPTIDES
DK3894410T3 (da) Substituerede xanthinderivater
DK3738452T3 (da) Fordamper
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
EP3953090C0 (de) Reibahle
EP4063289C0 (en) CROWN CAPSULE